Kyowa Kirin to Invest $530M in New North American Biologics Manufacturing Facility

URLhttps://www.contractpharma.com/contents/view_break
SourceContract Pharma
Date Published06/10/2024

Additional Reshoring Information:

Company/Division name Kyowa Kirin
Type of work Manufacturing
Reshoring category:Foreign Direct Investment
Total number of jobs (added or to be added):100
Year reshoring announced:2024
Year reshoring implemented or to be implemented:2027
Domestically, the work will be done:In-house
Capital investment ($):530
Country(ies) from which reshored:Japan
City reshored to:Sanford
State(s) reshored to:NC
If relevant, work nearshored to:-
Industry(ies):Chemicals
Product(s) reshoredbiologics, pharmaceuticals
What domestic positive factors made reshoring more attractive?Government Incentives, Impact on domestic economy, Skilled workforce availability/training
Government Incentive dollar amount:$10 million
Find Reshoring Articles